This is a record in the pharmaceutical industry.
Bristol Myers Squibb (BMS) is preparing to market thirteen new treatments in France this year.
Almost all of these new molecules or indications aim to treat cancer patients.
This dynamism is the consequence of significant investments in R&D, most of which concerns oncology and hematology (blood cancers),
comments Christophe Durand, head of BMS in France.
It is also the fruit of an external growth strategy which has intensified in recent years
After the $74 billion takeover of Celgene three years ago, the biggest acquisition in pharma history, BMS got its hands on Myocardia in 2021 and Turning Point Therapeutics last May.
The American laboratory has thus doubled its pipeline over the past two years.
Having become the world's number 6 pharmaceutical company, BMS, which invests a quarter of its turnover in R&D, one of the…
This article is for subscribers only.
You have 73% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT